Janux Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Janux Therapeutics, Inc. (JANX) reported Increase (Decrease) in Deferred Revenue of $36.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-06
- Janux Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$10.12M.
- Janux Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was $46.27M.
- Janux Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $0.00.
- Janux Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- Janux Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was $0.00.
- Janux Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$1.71M.
- Janux Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$5.92M, a 435.71% decline from fiscal 2022.
- Janux Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $1.76M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $36.15M 10-Q · filed 2026-08-06 | $36.15M derived: sum of 3 quarters · filed 2026-08-06 | $36.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $46.27M 10-Q · filed 2026-05-07 | $46.27M derived: sum of 2 quarters · filed 2026-05-07 | $46.27M derived: sum of 3 quarters · filed 2026-05-07 | $46.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | -$94.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | -$94.00K derived: sum of 3 quarters · filed 2026-05-07 | -$972.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$94.00K derived: sum of 2 quarters · filed 2026-02-26 | -$972.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$972.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.71M 10-Q · filed 2025-11-06 | -$3.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$878.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.61M 10-Q · filed 2025-08-07 | -$3.55M derived: sum of 3 quarters · filed 2026-02-26 | -$5.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$733.00K 10-Q · filed 2025-05-08 | -$2.68M derived: sum of 2 quarters · filed 2026-02-26 | -$4.67M derived: sum of 3 quarters · filed 2026-02-26 | -$5.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.94M derived: sum of 2 quarters · filed 2026-02-26 | -$4.62M derived: sum of 3 quarters · filed 2026-02-26 | -$5.92M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$2.68M derived: sum of 2 quarters · filed 2024-11-06 | -$3.98M 10-Q · filed 2024-11-06 | -$6.07M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$682.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$1.98M 10-Q · filed 2024-08-07 | -$4.08M derived: sum of 3 quarters · filed 2025-02-27 | -$5.01M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$1.30M 10-Q · filed 2024-05-08 | -$3.39M derived: sum of 2 quarters · filed 2025-02-27 | -$4.33M derived: sum of 3 quarters · filed 2025-02-27 | $1.68M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$3.03M derived: sum of 2 quarters · filed 2025-02-27 | $2.98M derived: sum of 3 quarters · filed 2025-02-27 | $1.76M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$938.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.07M derived: sum of 2 quarters · filed 2023-11-07 | $3.86M 10-Q · filed 2023-11-07 | $2.62M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $6.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.80M 10-Q · filed 2023-08-08 | $3.56M derived: sum of 3 quarters · filed 2023-08-08 | $2.77M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$1.21M 10-Q · filed 2023-05-09 | -$2.46M derived: sum of 2 quarters · filed 2023-05-09 | -$3.24M derived: sum of 3 quarters · filed 2023-05-09 | -$3.35M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$2.02M derived: sum of 2 quarters · filed 2023-03-10 | -$2.13M derived: sum of 3 quarters · filed 2023-03-10 | -$2.14M 10-K · filed 2023-03-10 |
| 2021-09-30 | -$784.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$892.00K derived: sum of 2 quarters · filed 2022-11-10 | -$896.00K 10-Q · filed 2022-11-10 | $7.10M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$112.00K 10-Q · filed 2022-08-09 | $7.89M derived: sum of 3 quarters · filed 2022-08-09 | $7.89M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$4.00K 10-Q · filed 2022-05-10 | $8.00M derived: sum of 2 quarters · filed 2022-05-10 | $8.00M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $8.00M derived: sum of 2 quarters · filed 2022-03-18 | $8.00M 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |